Gilead Sciences Inc

GILD

Equity

ISIN US3755581036 / Valor 935700

NASDAQ (2024-09-18)

USD 83.89+1.01%

Gilead Sciences Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Gilead Sciences Inc is a biopharmaceutical company that focuses on developing innovative therapies to treat life-threatening diseases. The company is known for its research and development in areas such as HIV/AIDS, liver diseases, and cancer. Gilead is committed to maintaining high standards of corporate accounting and financial reporting practices, ensuring the accuracy and transparency of its financial statements. The company also places importance on internal controls and the performance of its auditors to uphold the integrity of its financial reports.

Summarized from source with an LLMView SourceSector: Technology

Total Revenue

Gilead Sciences Inc. reported a total revenue increase of 5% to $7.0 billion for the second quarter of 2024, compared to the same period in 2023. This growth was primarily driven by higher product sales in HIV, Liver Disease, and Oncology.

Earnings Per Share

For the second quarter of 2024, Gilead Sciences Inc. reported a diluted earnings per share (EPS) of $1.29, up from $0.83 in the same period in 2023. The increase was mainly due to lower operating expenses and higher revenues.

Product Sales

Gilead Sciences Inc.'s total product sales for the second quarter of 2024 increased by 5% to $6.9 billion. Excluding Veklury, product sales rose by 6% to $6.7 billion, driven by higher sales in HIV, Liver Disease, and Oncology.

Cash and Equivalents

As of June 30, 2024, Gilead Sciences Inc. had $2.8 billion in cash, cash equivalents, and marketable debt securities, down from $8.4 billion as of December 31, 2023. The decrease was primarily due to the $3.9 billion acquisition of CymaBay Therapeutics, Inc. and a $1.75 billion repayment of senior notes.

Dividends and Stock Repurchase

During the second quarter of 2024, Gilead Sciences Inc. paid dividends amounting to $972 million and repurchased $100 million of common stock. This reflects the company's commitment to returning value to its shareholders.

Summarized from source with an LLMView Source

Key figures

10.9%1Y

17.1%3Y

27.6%5Y

Performance

24.3%1Y

23.0%3Y

26.1%5Y

Volatility